Silk Road Medical Inc
SILK
9.95USD+0.22Â (+2.26%)Market ClosedWatchlist
Market Summary
USD9.95+0.22
Market Closed2.26%
SILK Stock Price
View Fullscreen
SILK RSI Chart
SILK Valuation
SILK Price/Sales (Trailing)
SILK Profitability
SILK Fundamentals
SILK Revenue
SILK Earnings
Price Action
Last 7 days
20.3%
Last 30 days
13.6%
Last 90 days
-47.2%
Trailing 12 Months
-81.7%
How does SILK drawdown profile look like?
SILK Financial Health
SILK Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 150.7M | 162.9M | 169.9M | 0 |
| 2022 | 107.4M | 114.2M | 126.8M | 138.6M |
| 2021 | 78.3M | 89.7M | 94.3M | 101.5M |
| 2020 | 69.5M | 69.7M | 72.7M | 75.2M |
| 2019 | 41.6M | 48.8M | 56.2M | 63.4M |
| 2018 | 22.8M | 26.9M | 30.8M | 34.6M |
| 2017 | 0 | 0 | 0 | 14.3M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SILK
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 02, 2023 | mckhann chas | acquired | - | - | 612,083 | chief executive officer |
| Oct 27, 2023 | jones marie l. | sold | -4,334 | 6.607 | -656 | cao and vp, finance |
| Oct 04, 2023 | buchanan lucas w. | sold | -40,523 | 15.223 | -2,662 | coo/cfo |
| Sep 15, 2023 | klemz kevin m | acquired | - | - | 86,076 | evp/chief legal officer/sec. |
| Sep 15, 2023 | davis andrew s. | acquired | - | - | 121,519 | chief commercial officer |
| Sep 15, 2023 | buchanan lucas w. | acquired | - | - | 222,785 | coo/cfo |
| Sep 15, 2023 | ruedy richard | acquired | - | - | 28,354 | evpclin®.affairs&qa |
| Sep 15, 2023 | jones marie l. | acquired | - | - | 7,595 | cao and vp, finance |
| Aug 17, 2023 | klemz kevin m | sold | -30,941 | 20.105 | -1,539 | evp/chief legal officer/sec. |
| Aug 03, 2023 | davis andrew s. | sold | -145,797 | 22.134 | -6,587 | chief commercial officer |
Which funds bought or sold SILK recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -93.5 | -10,639,600 | 328,806 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | new | - | 298,915 | 298,915 | 0.01% |
| Nov 21, 2023 | Walleye Capital LLC | new | - | 213,308 | 213,308 | -% |
| Nov 21, 2023 | COMERICA BANK | new | - | 9,402 | 9,402 | -% |
| Nov 17, 2023 | TimesSquare Capital Management, LLC | sold off | -100 | -12,259,000 | - | -% |
| Nov 16, 2023 | Financial Gravity Asset Management, Inc. | sold off | -100 | -61.00 | - | -% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | added | 215 | 222,865 | 713,659 | -% |
| Nov 15, 2023 | Bullseye Asset Management LLC | added | 39.82 | -921,000 | 1,675,000 | 0.93% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | added | 384 | 541,896 | 980,316 | 0.01% |
| Nov 15, 2023 | iA Global Asset Management Inc. | sold off | -100 | -1,974,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Silk Road Medical Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Oct 20, 2023 | flynn james e | 0.00% | 0 | SC 13G | |
| Aug 10, 2023 | alliancebernstein l.p. | 0.1% | 46,800 | SC 13G/A | |
| May 10, 2023 | wasatch advisors lp | - | 0 | SC 13G/A | |
| Feb 14, 2023 | alliancebernstein l.p. | 6.9% | 2,616,795 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 7.8% | 2,966,730 | SC 13G/A | |
| Feb 10, 2023 | flynn james e | 3.66% | 1,396,640 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.34% | 3,562,110 | SC 13G/A | |
| Feb 08, 2023 | wasatch advisors inc | - | 0 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.0% | 2,664,762 | SC 13G/A | |
| Apr 11, 2022 | alliancebernstein l.p. | 10.7% | 3,747,528 | SC 13G/A |
Recent SEC filings of Silk Road Medical Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 08, 2023 | 10-Q | Quarterly Report | |
| Nov 08, 2023 | 8-K | Current Report | |
| Nov 06, 2023 | 144 | Notice of Insider Sale Intent | |
| Nov 03, 2023 | 3 | Insider Trading | |
| Nov 03, 2023 | 4 | Insider Trading | |
| Nov 02, 2023 | 8-K | Current Report | |
| Oct 30, 2023 | 4 | Insider Trading | |
| Oct 20, 2023 | SC 13G | Major Ownership Report | |
| Oct 10, 2023 | 8-K | Current Report | |
| Oct 06, 2023 | 4 | Insider Trading |
Peers (Alternatives to Silk Road Medical Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABT | 183.0B | 40.0B | 9.73% | -2.70% | 35.46 | 4.58 | -11.26% | -34.57% |
BDX | 71.3B | 19.4B | -8.25% | -5.16% | 44.09 | 3.79 | 2.66% | -16.58% |
BAX | 18.7B | 15.0B | 8.63% | -30.19% | 7.2 | 1.24 | 3.01% | 209.09% |
ALGN | 16.8B | 3.8B | 11.22% | 10.68% | 46.36 | 4.42 | -1.48% | -28.97% |
| MID-CAP | ||||||||
HSIC | 9.0B | 12.7B | 11.09% | -16.77% | 20.24 | 0.71 | 0.68% | -30.25% |
BIO | 9.0B | 2.7B | 7.31% | -26.28% | -56.42 | 3.3 | -3.01% | 97.36% |
ATR | 8.4B | 3.4B | 2.45% | 18.85% | 30.02 | 2.45 | 3.13% | 18.17% |
XRAY | 6.9B | 3.9B | 12.08% | 3.35% | -31.81 | 1.76 | -2.62% | 73.28% |
AXNX | 2.9B | 342.6M | 6.85% | -17.46% | -245.59 | 8.59 | 42.19% | 84.14% |
PDCO | 2.5B | 6.6B | -16.25% | -11.02% | 12.27 | 0.37 | 2.61% | 0.62% |
| SMALL-CAP | ||||||||
AHCO | 1.2B | 3.1B | 8.50% | -59.80% | -2.91 | 0.4 | 7.95% | -550.16% |
ANIK | 333.0M | 163.3M | 7.72% | -27.92% | -13.55 | 2.04 | 7.14% | -56.09% |
ANGO | 271.9M | 335.9M | -0.73% | -44.59% | 42.18 | 0.81 | 4.71% | 116.39% |
APYX | 74.8M | 50.3M | -17.56% | 18.68% | -4.94 | 1.49 | 3.23% | 20.81% |
AEMD | 5.1M | 3.8M | 9.63% | -51.71% | -0.44 | 1.34 | 17.30% | 10.67% |
Silk Road Medical Inc News
Latest updates
Financials for Silk Road Medical Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -1.9% | 44,435,000 | 45,298,000 | 40,131,000 | 40,071,000 | 37,374,000 | 33,173,000 | 28,021,000 | 28,265,000 | 24,701,000 | 26,456,000 | 22,053,000 | 21,133,000 | 20,067,000 | 15,094,000 | 18,933,000 | 18,634,000 | 17,026,000 | 14,928,000 | 12,766,000 | 11,470,000 | 9,614,000 |
| Gross Profit | 0.3% | 32,385,000 | 32,294,000 | 27,605,000 | 29,092,000 | 28,066,000 | 24,161,000 | 19,444,000 | 21,032,000 | 18,625,000 | 19,858,000 | 16,515,000 | 15,916,000 | 14,579,000 | 9,758,000 | 13,683,000 | 13,913,000 | 12,856,000 | 11,231,000 | 9,427,000 | 7,803,000 | 6,732,000 |
| Operating Expenses | -1.2% | 46,056,000 | 46,610,000 | 44,515,000 | 41,722,000 | 37,292,000 | 38,355,000 | 35,398,000 | 35,094,000 | 31,916,000 | 29,810,000 | 26,678,000 | 30,911,000 | 23,913,000 | 19,151,000 | 22,823,000 | 21,420,000 | 20,251,000 | 17,248,000 | 16,573,000 | 15,102,000 | 11,415,000 |
| S&GA Expenses | 0.5% | 36,009,000 | 35,830,000 | 34,082,000 | 32,522,000 | 28,821,000 | 27,700,000 | 27,275,000 | 27,595,000 | 25,049,000 | 22,549,000 | 21,194,000 | 20,872,000 | 19,202,000 | 15,758,000 | 19,692,000 | 18,156,000 | 17,064,000 | 14,135,000 | 13,866,000 | 11,712,000 | 8,973,000 |
| R&D Expenses | -6.8% | 10,047,000 | 10,780,000 | 10,433,000 | 9,200,000 | 8,471,000 | 10,655,000 | 8,123,000 | 7,499,000 | 6,867,000 | 7,261,000 | 5,484,000 | 10,039,000 | 4,711,000 | 3,393,000 | 3,131,000 | 3,264,000 | 3,187,000 | 3,113,000 | 2,707,000 | 3,390,000 | 2,442,000 |
| EBITDA Margin | - | - | - | - | - | - | -0.41 | -0.44 | -0.47 | - | - | -0.55 | -0.56 | -0.64 | -0.67 | -0.67 | -0.74 | -0.57 | -0.66 | -0.78 | - | - |
| Interest Expenses | 1.2% | 1,732,000 | 1,712,000 | 1,693,000 | 1,732,000 | 1,714,000 | 1,031,000 | 621,000 | 634,000 | 633,000 | 628,000 | 623,000 | 791,000 | 1,215,000 | 1,203,000 | 1,202,000 | 1,216,000 | 1,176,000 | 1,207,000 | 1,352,000 | 1,296,000 | 1,065,000 |
| EBT Margin | - | - | - | - | - | - | -0.44 | -0.46 | -0.49 | - | - | -0.60 | -0.63 | -0.72 | -0.75 | -0.75 | -0.83 | -0.67 | -0.77 | -0.90 | - | - |
| Net Income | 5.2% | -12,788,000 | -13,484,000 | -16,460,000 | -12,614,000 | -10,319,000 | -15,398,000 | -16,679,000 | -14,693,000 | -13,885,000 | -10,539,000 | -10,694,000 | -16,756,000 | -10,315,000 | -10,353,000 | -9,941,000 | -8,291,000 | -8,007,000 | -11,959,000 | -24,158,000 | -15,618,000 | -8,953,000 |
| Net Income Margin | - | - | - | -0.36 | -0.40 | -0.45 | -0.53 | -0.52 | -0.49 | -0.55 | -0.54 | -0.61 | -0.63 | -0.53 | -0.53 | -0.55 | -0.83 | - | - | - | - | - |
| Free Cashflow | - | - | - | -12,434,000 | -4,291,000 | -5,115,000 | -11,383,000 | -16,797,000 | -14,184,000 | -7,627,000 | -9,843,000 | -12,039,000 | -14,524,000 | -4,531,000 | -11,926,000 | -11,929,000 | -5,459,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2017Q4 |
| Assets | -0.9% | 261 | 263 | 260 | 270 | 163 | 163 | 143 | 157 | 166 | 168 | 170 | 179 | 184 | 188 | 127 | 137 | 139 | 143 | 39.00 | 43.00 | 43.00 |
| Current Assets | 3.2% | 241 | 233 | 230 | 255 | 147 | 147 | 128 | 143 | 154 | 159 | 164 | 173 | 178 | 181 | 120 | 112 | 132 | 136 | 29.00 | 39.00 | 42.00 |
| Cash Equivalents | 2.8% | 29.00 | 28.00 | 50.00 | 55.00 | 51.00 | 88.00 | 94.00 | 110 | 106 | 102 | 95.00 | 70.00 | 63.00 | 74.00 | 28.00 | 39.00 | 113 | 119 | 16.00 | 25.00 | 34.00 |
| Inventory | 15.7% | 22.00 | 19.00 | 17.00 | 19.00 | 20.00 | 18.00 | 18.00 | 18.00 | 16.00 | 13.00 | 12.00 | 10.00 | 11.00 | 12.00 | 12.00 | 10.00 | 9.00 | 9.00 | 8.00 | 6.00 | 3.00 |
| Net PPE | -3.6% | 8.00 | 9.00 | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 | 8.00 | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 0.00 |
| Liabilities | -0.1% | 108 | 108 | 102 | 106 | 105 | 103 | 75.00 | 77.00 | 77.00 | 72.00 | 69.00 | 72.00 | 64.00 | 60.00 | 63.00 | 66.00 | 61.00 | 58.00 | 91.00 | 72.00 | 36.00 |
| Current Liabilities | -0.3% | 24.00 | 24.00 | 21.00 | 24.00 | 24.00 | 21.00 | 29.00 | 26.00 | 21.00 | 17.00 | 16.00 | 20.00 | 15.00 | 12.00 | 14.00 | 17.00 | 12.00 | 9.00 | 11.00 | 11.00 | 5.00 |
| Short Term Borrowings | - | - | - | - | - | - | - | 10.00 | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | 0.3% | 75.00 | 75.00 | 75.00 | 75.00 | 74.00 | 74.00 | 39.00 | 45.00 | 49.00 | 49.00 | 49.00 | 49.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 44.00 | 28.00 |
| Shareholder's Equity | -1.5% | 153 | 156 | 158 | 164 | 57.00 | 60.00 | 68.00 | 79.00 | 88.00 | 96.00 | 101 | 108 | 120 | 127 | 64.00 | 72.00 | 77.00 | 84.00 | - | - | - |
| Retained Earnings | -3.4% | -386 | -373 | -360 | -343 | -331 | -320 | -305 | -288 | -274 | -260 | -249 | -238 | -222 | -211 | -201 | -191 | -183 | -175 | -163 | -139 | -101 |
| Additional Paid-In Capital | 2.0% | 540 | 529 | 518 | 508 | 388 | 381 | 373 | 368 | 362 | 356 | 351 | 346 | 342 | 339 | 265 | 263 | 261 | 260 | 5.00 | 5.00 | 3.00 |
| Shares Outstanding | 0.2% | 39.00 | 39.00 | 39.00 | 38.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 34.00 | 34.00 | 34.00 | 32.00 | 31.00 | 23.00 | 31.00 | 28.00 | - | 1.00 | 1.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -47.3% | -6,798 | -4,616 | -12,147 | -2,724 | -4,726 | -10,406 | -14,725 | -11,432 | -6,495 | -9,036 | -11,972 | -14,269 | -4,423 | -11,581 | -11,795 | -5,261 | -6,346 | -9,383 | -8,620 | -5,390 | -6,367 |
| Share Based Compensation | 0.5% | 10,247 | 10,199 | 8,838 | 7,545 | 6,339 | 6,161 | 4,978 | 3,984 | 3,686 | 3,409 | 3,533 | 2,273 | 2,006 | 1,654 | 1,293 | 954 | 924 | 837 | 262 | 226 | 194 |
| Cashflow From Investing | 138.9% | 7,456 | -19,158 | 6,106 | -104,951 | -32,895 | -22,150 | -2,072 | 14,250 | 7,968 | 14,193 | 36,233 | 12,898 | -7,386 | -14,797 | -108 | -69,619 | -131 | -89.00 | -117 | -102 | -1,164 |
| Cashflow From Financing | -91.8% | 130 | 1,592 | 1,110 | 111,727 | 1,213 | 26,591 | 168 | 1,771 | 2,242 | 2,117 | 848 | 8,369 | 835 | 72,268 | 274 | 1,784 | 507 | 112,210 | -744 | -226 | 15,218 |
SILK Income Statement
2023-09-30Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Condensed Statements of Operations and Comprehensive Loss [Abstract] | ||||
| Revenue | $ 44,435 | $ 37,374 | $ 129,864 | $ 98,567 |
| Cost of goods sold | 12,050 | 9,308 | 37,580 | 26,897 |
| Gross profit | 32,385 | 28,066 | 92,284 | 71,670 |
| Operating expenses: | ||||
| Research and development | 10,047 | 8,471 | 31,260 | 27,249 |
| Selling, general and administrative | 36,009 | 28,821 | 105,923 | 83,795 |
| Total operating expenses | 46,056 | 37,292 | 137,183 | 111,044 |
| Loss from operations | (13,671) | (9,226) | (44,899) | (39,374) |
| Interest income | 2,617 | 617 | 7,339 | 751 |
| Interest expense | (1,732) | (1,714) | (5,137) | (3,366) |
| Loss on debt extinguishment | (245) | |||
| Other income (expense), net | (2) | 4 | (35) | (162) |
| Net loss | (12,788) | (10,319) | (42,732) | (42,396) |
| Other comprehensive loss: | ||||
| Unrealized gain (loss) on investments, net | 47 | (189) | (118) | (191) |
| Other comprehensive loss | 47 | (189) | (118) | (191) |
| Net loss and comprehensive loss | $ (12,741) | $ (10,508) | $ (42,850) | $ (42,587) |
| Net loss per share, basic | $ (0.33) | $ (0.29) | $ (1.10) | $ (1.21) |
| Net loss per share, diluted | $ (0.33) | $ (0.29) | $ (1.10) | $ (1.21) |
| Weighted average common shares used to compute net loss per share, basic | 38,865,011 | 35,303,958 | 38,722,012 | 35,157,840 |
| Weighted average common shares used to compute net loss per share, diluted | 38,865,011 | 35,303,958 | 38,722,012 | 35,157,840 |
SILK Balance Sheet
2023-09-30Condensed Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 29,188 | $ 55,358 |
| Short-term investments | 163,673 | 158,316 |
| Accounts receivable, net | 21,779 | 18,007 |
| Inventories | 22,066 | 19,293 |
| Prepaid expenses and other current assets | 4,277 | 3,924 |
| Total current assets | 240,983 | 254,898 |
| Long-term investments | 4,348 | |
| Property and equipment, net | 8,337 | 9,372 |
| Restricted cash | 0 | 155 |
| Other non-current assets | 7,196 | 5,260 |
| Total assets | 260,864 | 269,685 |
| Current liabilities: | ||
| Accounts payable | 5,094 | 2,523 |
| Accrued liabilities | 18,928 | 21,965 |
| Total current liabilities | 24,022 | 24,488 |
| Long-term debt | 75,364 | 74,596 |
| Other liabilities | 8,336 | 6,726 |
| Total liabilities | 107,722 | 105,810 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value Shares authorized: 5,000,000 at September 30, 2023 and December 31, 2022 Shares issued and outstanding: none at September 30, 2023 and December 31, 2022 | ||
| Common stock, $0.001 par value Shares authorized: 100,000,000 at September 30, 2023 and December 31, 2022 Shares issued and outstanding: 38,907,789 and 38,355,972 at September 30, 2023 and December 31, 2022, respectively | 39 | 38 |
| Additional paid-in capital | 539,831 | 507,715 |
| Accumulated other comprehensive loss | (284) | (166) |
| Accumulated deficit | (386,444) | (343,712) |
| Total stockholders’ equity | 153,142 | 163,875 |
| Total liabilities and stockholders’ equity | $ 260,864 | $ 269,685 |
| Â CEO | Ms. Erica J. Rogers |
|---|---|
| Â WEBSITE | silkroadmed.com |
| Â EMPLOYEES | 414 |